Please Wait
Applying Filters...
menu
    • menu
    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

    Virtual Booth

    Contact Supplier

    Boai NKY Pharmaceuticals Ltd. is one of the largest global PVP suppliers.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-06-09

    Virtual Booth

    An Enquiry

    Menu

    Nusinersen Sodium

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 1,878,602Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 2SPINRAZA royalties

    02 9Spinraza

    03 3Spinraza Royalties

    PharmaCompass
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Spinraza

    Nusinersen

    arrow
    IOPC
    Not Confirmed

    Brand Name : Spinraza

    U.S.A
    arrow
    IOPC
    Not Confirmed

    Biogen

    Nusinersen

    Main Therapeutic Indication : Genetic Disorders

    Currency : USD

    2020 Revenue in Millions : 2,052

    2019 Revenue in Millions : 2,097

    Growth (%) : -2

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : SPINRAZA royalties

    Nusinersen

    arrow
    IOPC
    Not Confirmed

    Brand Name : SPINRAZA royalties

    U.S.A
    arrow
    IOPC
    Not Confirmed

    Ionis Pharmaceuticals

    Nusinersen

    Main Therapeutic Indication : Genetic Disorders

    Currency : USD

    2020 Revenue in Millions : 287

    2019 Revenue in Millions : 293

    Growth (%) : -2

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Spinraza

    Nusinersen

    arrow
    IOPC
    Not Confirmed

    Brand Name : Spinraza

    U.S.A
    arrow
    IOPC
    Not Confirmed

    Biogen

    Nusinersen

    Main Therapeutic Indication : Genetic Disorders

    Currency : USD

    2021 Revenue in Millions : 1,905

    2020 Revenue in Millions : 2,052

    Growth (%) : -7

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : SPINRAZA royalties

    Nusinersen

    arrow
    IOPC
    Not Confirmed

    Brand Name : SPINRAZA royalties

    U.S.A
    arrow
    IOPC
    Not Confirmed

    Ionis Pharmaceuticals

    Nusinersen

    Main Therapeutic Indication : Genetic Disorders

    Currency : USD

    2021 Revenue in Millions : 268

    2020 Revenue in Millions : 287

    Growth (%) : -7

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Spinraza Royalties

    Nusinersen

    arrow
    IOPC
    Not Confirmed

    Brand Name : Spinraza Royalties

    U.S.A
    arrow
    IOPC
    Not Confirmed

    Ionis Pharmaceuticals

    Nusinersen

    Main Therapeutic Indication : Genetic Diseases

    Currency : USD

    2022 Revenue in Millions : 242

    2021 Revenue in Millions : 268

    Growth (%) : -10

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Brand Name : Spinraza

    Nusinersen

    arrow
    IOPC
    Not Confirmed

    Brand Name : Spinraza

    U.S.A
    arrow
    IOPC
    Not Confirmed

    Biogen

    Nusinersen

    Main Therapeutic Indication : Genetic Diseases

    Currency : USD

    2022 Revenue in Millions : 1,794

    2021 Revenue in Millions : 1,905

    Growth (%) : -6

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Brand Name : Spinraza Royalties

    Nusinersen

    arrow
    IOPC
    Not Confirmed

    Brand Name : Spinraza Royalties

    U.S.A
    arrow
    IOPC
    Not Confirmed

    Ionis Pharmaceuticals

    Nusinersen

    Main Therapeutic Indication : Genetic Diseases

    Currency : USD

    2023 Revenue in Millions : 240

    2022 Revenue in Millions : 242

    Growth (%) : -1

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Brand Name : Spinraza

    Nusinersen

    arrow
    IOPC
    Not Confirmed

    Brand Name : Spinraza

    U.S.A
    arrow
    IOPC
    Not Confirmed

    Biogen

    Nusinersen

    Main Therapeutic Indication : Genetic Diseases

    Currency : USD

    2023 Revenue in Millions : 1,741

    2022 Revenue in Millions : 1,794

    Growth (%) : -3

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Brand Name : Spinraza

    Nusinersen

    arrow
    IOPC
    Not Confirmed

    Brand Name : Spinraza

    U.S.A
    arrow
    IOPC
    Not Confirmed

    Biogen

    Nusinersen

    Main Therapeutic Indication : Genetic Diseases

    Currency : USD

    2024 Revenue in Millions : 1,573

    2023 Revenue in Millions : 1,741

    Growth (%) : -10

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Brand Name : Spinraza Royalties

    Nusinersen

    arrow
    IOPC
    Not Confirmed

    Brand Name : Spinraza Royalties

    U.S.A
    arrow
    IOPC
    Not Confirmed

    Ionis Pharmaceuticals

    Nusinersen

    Main Therapeutic Indication : Genetic Diseases

    Currency : USD

    2024 Revenue in Millions : 216

    2023 Revenue in Millions : 240

    Growth (%) : -10

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF